Diagnostic Accuracy of Smartphone-Enabled Urinary Albumin-to-Creatinine Ratio Testing
Authors:
- 11 July 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 10 (5) , 1241-1253
Abstract
Background: Albuminuria is an important biomarker for detecting chronic kidney disease (CKD), particularly in at-risk individuals. Advances in diagnostic technology have introduced home-use, semiquantitative testing methods such as the FDA-cleared Minuteful Kidney Test (MKT). This study compares the diagnostic accuracy of the MKT to the Beckman Coulter AU 480 analyzer, a standard laboratory quantitative method, for detecting albuminuria in individuals with or at risk for CKD. Methods: Urine samples were obtained from individuals with risk factors for kidney damage. Each sample was analyzed for the urinary albumin-to-creatinine ratio (uACR) using both the MKT and the laboratory standard method. Albuminuria was classified according to KDIGO guidelines: A1 (uACR 300 mg/g, “severely increased”). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MKT were calculated against the laboratory standard. Results: Out of 615 collected urine samples, 555 met inclusion criteria. Albuminuria (uACR >30 mg/g) was detected in 24.9% of samples using the laboratory method (95% CI: 21.3%–28.5%). The MKT demonstrated a sensitivity of 96.4%, specificity of 84.2%, NPV of 98.6%, and PPV of 66.8%. MKT accurately categorized 85.6% of samples into the KDIGO albuminuria categories A1, A2, and A3, identifying 100% of laboratory-confirmed A3 samples as abnormal. Conclusions: The MKT shows high sensitivity, exceeding the guideline-required threshold (>85%, P < 0.001), and acceptable specificity for detecting albuminuria in high-risk populations. This device offers the potential to improve CKD detection and management and facilitate early intervention in primary care and community settings, where accurate rule-out capabilities are essential.Keywords
Funding Information
- Canadian Institutes of Health Research
- National Institutes of Health
- Kidney Foundation of Canada
- Bayer
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceutica
- Research Manitoba
- Otsuka Pharmaceutical Co., Ltd
- Tricida
- Eli Lilly and Company
This publication has 15 references indexed in Scilit:
- Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gapsClinical Kidney Journal, 2023
- Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims DatabaseMayo Clinic Proceedings, 2021
- Chronic Kidney DiseaseThe Lancet, 2017
- Prevalence and Determinants of Chronic Kidney Disease Among Hypertensive Cameroonians According to Three Common Estimators of the Glomerular Filtration RateThe Journal of Clinical Hypertension, 2016
- A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010Kidney International, 2015
- Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohortsKidney International, 2011
- Relation Between Kidney Function, Proteinuria, and Adverse OutcomesJAMA, 2010
- Current Issues in Measurement and Reporting of Urinary Albumin ExcretionClinical Chemistry, 2009
- Albuminuria Assessed From First-Morning-Void Urine Samples Versus 24-Hour Urine Collections as a Predictor of Cardiovascular Morbidity and MortalityAmerican Journal of Epidemiology, 2008
- Association of Kidney Function and Albuminuria With Cardiovascular Mortality in Older vs Younger IndividualsArchives of internal medicine (1960), 2007